GlassScriptPhysician profile
Daniel James Kruger
NPI 1619684842
$2,156.63
in general payments reported to CMS, 2019-2025
32 companies · $756 in 2025
The $756 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $731 · 2024: $670 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.30 | 2023-2025 | |
| Pfizer INC. | $286.83 | 2023-2025 | |
| Novo Nordisk INC | $182.33 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $161.60 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $87.35 | 2023-2025 | Airsupra |
| Exact Sciences Corporation | $83.54 | 2023-2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $79.05 | 2023-2025 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.06 | 2023-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $54.46 | 2023-2024 | Nuedexta |
| Idorsia Pharmaceuticals US INC | $49.25 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $49.11 | 2023-2024 | Belsomra, Steglatro, Gardasil 9 |
| Sumitomo Pharma America, INC. | $44.49 | 2024-2025 | Gemtesa |
| Ibsa Pharma INC. | $42.68 | 2025 | Licart, Flector, Tirosint |
| Abbott Laboratories | $39.90 | 2024-2025 | Freestyle Libre 3, Eterna |
| Radius Health, INC. | $28.95 | 2023 | Tymlos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.89 | 2025 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $28.84 | 2024 | Spravato |
| Lilly USA, LLC | $27.60 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Edwards Lifesciences Corporation | $26.79 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $25.27 | 2024 | |
| Novartis Pharmaceuticals Corporation | $25.13 | 2024 | |
| Inogen, INC. | $25.00 | 2023 | Inogen |
| Lundbeck LLC | $24.49 | 2023 | Rexulti |
| Lucid Diagnostics INC. | $22.24 | 2024 | |
| Abiomed | $19.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.70 | 2024 | Trintellix |
| Daiichi Sankyo INC. | $17.52 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $16.37 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.27 | 2024 | Eliquis |
| Glaxosmithkline, LLC. | $15.03 | 2025 | Shingrix, Arexvy |
| Aimmune Therapeutics, INC. | $14.74 | 2024 | |
| Tactile Systems Technology INC | $12.83 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kruger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.